Improving Radiation Therapy Of Static And Moving Targets Using High Spatial Resolution Real-time Dosimeters
Funder
National Health and Medical Research Council
Funding Amount
$544,425.00
Summary
Radiation therapy is a major oncology modality for cancer treatment and more than 50% of cancer patients can benefit from radiotherapy at some stage of management. This project will develop two real-time, high spatial resolution dosimetry systems for quality assurance of contemporary radiation treatments of static and movable targets. It will be possible to minimize human and robotic system error so as to guarantee accurate cancer treatment delivery and improve the clinical outcomes of radiother ....Radiation therapy is a major oncology modality for cancer treatment and more than 50% of cancer patients can benefit from radiotherapy at some stage of management. This project will develop two real-time, high spatial resolution dosimetry systems for quality assurance of contemporary radiation treatments of static and movable targets. It will be possible to minimize human and robotic system error so as to guarantee accurate cancer treatment delivery and improve the clinical outcomes of radiotherapy.Read moreRead less
Translating Synchrotron Microbeam Radiation Therapy Into A Clinical Reality For Cancer Patients
Funder
National Health and Medical Research Council
Funding Amount
$337,896.00
Summary
The aim of this project is to translate an experimental radiotherapy technique, known as microbeam radiotherapy, into a clinical reality for the benefit of cancer patients world-wide. I propose to achieve this aim by working at the European Synchrotron Radiation Facility (ESRF) in France. The ESRF is Europe’s most powerful synchrotron light source, where a multi-disciplinary team of scientists and physicians are collaborating to treat the first human cancer patients with synchrotron radiation.
A Computerised Treatment Planning System For Synchrotron Radiotherapy Trials At The Australian Synchrotron’s Imaging & Medical Beamline.
Funder
National Health and Medical Research Council
Funding Amount
$646,812.00
Summary
Microbeam Radiotherapy (MRT) using synchrotron-generated X-rays has shown tremendous promise in pre-clinical trials in tumour-bearing rodents, with remarkable sparing of normal tissue. Synchrotron MRT has the potential to radically alter the way radiotherapy is performed for human cancers. Every radiotherapy patient undergoes some form of computerised treatment planning before their treatment starts. We aim to test and implement a synchrotron Treatment Planning System, as an essential step in re ....Microbeam Radiotherapy (MRT) using synchrotron-generated X-rays has shown tremendous promise in pre-clinical trials in tumour-bearing rodents, with remarkable sparing of normal tissue. Synchrotron MRT has the potential to radically alter the way radiotherapy is performed for human cancers. Every radiotherapy patient undergoes some form of computerised treatment planning before their treatment starts. We aim to test and implement a synchrotron Treatment Planning System, as an essential step in realising synchrotron radiotherapy trials.Read moreRead less
A Multicentre Feasibility Study Of Partial Breast Irradiation Using 3D Conformal Radiotherapy For Early Breast Cancer
Funder
National Health and Medical Research Council
Funding Amount
$154,910.00
Summary
Breast conserving therapy (BCT) is an accepted treatment option for most women with early breast cancer. Whole breast irradiation (WBI) after breast conserving surgery substantially reduces the risk of breast recurrence. However, the prolonged 5-7 week course of WBI substantially decreases the quality of life (QoL) experienced by women and is a logistical problem particularly for the elderly and women who reside far from a radiotherapy (RT) facility. In order to improve the access and convenienc ....Breast conserving therapy (BCT) is an accepted treatment option for most women with early breast cancer. Whole breast irradiation (WBI) after breast conserving surgery substantially reduces the risk of breast recurrence. However, the prolonged 5-7 week course of WBI substantially decreases the quality of life (QoL) experienced by women and is a logistical problem particularly for the elderly and women who reside far from a radiotherapy (RT) facility. In order to improve the access and convenience of BCT, accelerated partial breast irradiation (APBI) is being investigated. Research shows that 75% of the breast recurrences occur at the tumour bed after BCT implying that in selected women, RT may be limited to the tumour bed only. By limiting the breast volume irradiated, it is feasible to accelerate radiation dose delivery and reduce overall treatment time. In addition, a shorter schedule permits more efficient use of RT resources. To determine if APBI could replace WBI as standard of care for selected women with early breast cancer treated with BCT, it is necessary to demonstrate its technical feasibility and equivalence of outcomes compared to WBI. This study investigates the feasibility, toxicity, cosmetic outcome, local control and QoL of women with early breast cancer treated with APBI using a novel technique. It uses advanced 3-dimensional RT planning and multiple fields shaped to conform to the target volume (tumour bed) and spare the normal organs. It is more likely than the other modalities to be adopted as the preferred APBI technique in Australia because it uses equipments readily available in most RT centres and being non-invasive, is likely to be preferred by patients. However, its feasibility in multiple Australian centres with varying RT equipments is unclear. Given the current high level of international interest, it is timely to conduct this feasibility study in preparation for large scale research to determine if APBI may replace WBI in BCT.Read moreRead less
Quality Assurance In LDR And HDR Prostate Brachytherapy
Funder
National Health and Medical Research Council
Funding Amount
$221,500.00
Summary
Prostate cancer is one of the most commonly diagnosed cancers in men over 55 years of age. Approximately 30% of all diagnosed cancers in this age group are prostate carcinomas. Low and high dose rate brachytherapy are newly established treatment options for early-stage, low-risk, prostate cancer and are an alternative to curative prostatectomy in most patients. Local control and cure of prostate cancer is greatly influenced by the dose distribution generated by both the treatment techniques. Tre ....Prostate cancer is one of the most commonly diagnosed cancers in men over 55 years of age. Approximately 30% of all diagnosed cancers in this age group are prostate carcinomas. Low and high dose rate brachytherapy are newly established treatment options for early-stage, low-risk, prostate cancer and are an alternative to curative prostatectomy in most patients. Local control and cure of prostate cancer is greatly influenced by the dose distribution generated by both the treatment techniques. Treatment plans must be able to deliver a prescribed dose in the tumour, with adequate margins, while minimising the dose delivered to the surrounding normal tissue and critical organs. It is well recognised that, however skilful the radiation oncologist, an ideal dose distribution according to a treatment plan plan does not guarantee a well delivered dose. Complications such as impotence, severe radiation urethritis and severe rectal bleeding will arise if overdosing of the neuro-vascular bundle, urethra and rectum occurs respectively. This project is based on newly developed instrumentation that will allow continuous, realtime, in vivo, monitoring of the radiation dose levels in the urethra and rectum during brachytherapy treatment of prostate cancer. Such monitoring of the treatment procedure, has been identified as a high priority by the American Brachytherapy Society. The technique will allow extensive in vivo and post treatment studies to be performed by clinicians so as to measure the dose levels currently received and identify the optimum acceptable dose levels for future procedures. The outcomes of this project may well be able to be utilised in other forms of brachytherapy treament (e.g. breast, cervical cancer) and other radiation treatment modailities (e.g. conventional radiotherapy and intensity modulated radiotherapy) to also reduce complications associated with these treatment modalities.Read moreRead less
First Ever System To Continuously And Directly Measure The Internal Anatomy To Guide Breast Cancer Radiation Treatment Under Deep Inspiration Breath Hold
Funder
National Health and Medical Research Council
Funding Amount
$409,766.00
Summary
We propose a first ever system to continuously and directly measure the internal anatomy of the patient during radiotherapy of left sided breast cancer to ensure correct position of patient and radiation beam. The proposed method involves no additional radiation dose to the patient. It relies on existing components of modern radiation treatment machines, requiring no additional equipment, which will make it easy to implement widely.
The proposed project is part of a research programme aimed at developing a new drug to reduce the side effects of cancer radiotherapy. These side effects result from the radiation damage to normal tissues close to the tumour. Since in many instances the normal tissues at risk are accessible to topical application (eg. skin in breast cancer patients, rectal mucosa in prostate cancer patients, oral mucosa in all patients being treated for tumours in the head and neck region) the concept is very si ....The proposed project is part of a research programme aimed at developing a new drug to reduce the side effects of cancer radiotherapy. These side effects result from the radiation damage to normal tissues close to the tumour. Since in many instances the normal tissues at risk are accessible to topical application (eg. skin in breast cancer patients, rectal mucosa in prostate cancer patients, oral mucosa in all patients being treated for tumours in the head and neck region) the concept is very simple. A drug which makes cells less sensitive to X-rays (these drugs are called radioprotectors) is simply applied topically to the normal tissues at risk. For this purpose, we have developed a new radioprotecting drug called methylproamine which is 100-fold more potent than previously-developed radioprotectors. Unfortunately, methylproamine is not suitable for our purpose because at higher concentrations it is toxic to some cells. This hurdle must be overcome in order to make the project attractive to potential commercial sponsors. Our aim is to modify methylproamine by removing the molecular features that cause the cytotoxicity. We have established that this is feasible, by synthesising and evaluating a small family of methylproamine analogues. Some less toxic family members have already been identified. With this knowledge, we now propose to use special computer programmes to design a much larger family of methylproamine analogues, and to synthesise and test each one in order to identify the most promising candidate for our purpose. Once the efficacy window hurdle is passed, the subsequent milestones to commercialisation and clinical implementation can be addressed, with appropriate sponsorship. An Australian company has already expressed strong interest and is evaluating the opportunity.Read moreRead less
Very Fast, Accurate And Low Dose Imaging For Radiotherapy Treatments
Funder
National Health and Medical Research Council
Funding Amount
$650,651.00
Summary
This project will reduce scan times and imaging dose by an order of magnitude for an imaging modality that is the standard of care for lung cancer patients receiving radiotherapy. Specifically, scan times reduce from 4min to below 60sec, image quality will be improved and imaging dose will be reduced by 85%. These improvements not only improve treatment efficacy by improving the accuracy of radiotherapy delivery, they reduce treatment times and reduce discomfort to the patient.
Stereotactic Body Radiotherapy (SBRT) As A New Standard Of Care For Spinal Metastases
Funder
National Health and Medical Research Council
Funding Amount
$200,148.00
Summary
Secondary spread of cancer to the spine affects about 40% of all cancer patients. The current standard of care, radiotherapy, does not provide durable control of cancer pain. Breakthrough technology in stereotactic body radiotherapy (SBRT) is showing considerable promise for improved patient outcomes. This study is a multi-national collaboration between Australia and Canada directly comparing conventional radiotherapy to spinal SBRT in order to establish spinal SBRT as the new standard of care.
Cancer Radiotherapy 2020: Accounting For Tumour Deformation In Real Time To Improve Treatment Outcome
Funder
National Health and Medical Research Council
Funding Amount
$371,616.00
Summary
Tumours in lung and prostate cancer change shape during radiotherapy treatment. This is not accounted for in current care, compromising the therapeutic efficacy. We will develop the first radiotherapy system that can adjust the radiation beam in real time to follow the changing tumour shape. We will assess the performance of the system and quantify the clinical benefit. It is expected that clinical implementation of this technique will improve the cure rates and decrease the treatment toxicity.